Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Clinical Trials
146
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (118 trials with phase data)• Click on a phase to view related trials
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: mRNA-4106
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT06880536
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: mRNA-4106
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT06880549
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
- Conditions
- InfluenzaSARS-CoV-2
- Interventions
- Biological: mRNA-1083 Composition 1 Dose A Lot ABiological: mRNA-1083 Composition 1 Dose A Lot BBiological: mRNA-1083 Composition 1 Dose BBiological: mRNA-1083 Composition 1 Dose CBiological: mRNA-1083 Composition 2 Dose ABiological: mRNA-1083 Composition 2 Dose BBiological: mRNA-1083 Composition 3 Dose ABiological: mRNA-1083 Composition 3 Dose BBiological: Investigational Influenza VaccineBiological: Investigational COVID-19 Vaccine Lot ABiological: Investigational COVID-19 Vaccine Lot B
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1300
- Registration Number
- NCT06864143
- Locations
- 🇺🇸
Headlands Research Scottsdale, Scottsdale, Arizona, United States
🇺🇸Artemis Research (Headlands), San Diego, California, United States
🇺🇸Clinical Research Atlanta (Headlands), Stockbridge, Georgia, United States
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT06735248
- Locations
- 🇺🇸
ANESC Research, El Paso, Texas, United States
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
- Conditions
- COVID-19Influenza
- Interventions
- Biological: Licensed Influenza VaccineOther: Placebo
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 2457
- Registration Number
- NCT06694389
- Locations
- 🇯🇵
Public Health Association.Inc., Nagoya-shi, Aichi, Japan
🇯🇵Daido Clinic, Nagoya-shi, Aichi, Japan
🇯🇵Tenjin Sogo Clinic, Fukuoka-shi, Fukuoka, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 21
- Next
News
EU Regulatory Approval Advances Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine for 2025-2026 Season
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.
Turkish Study Links Pfizer COVID-19 Vaccine to Corneal Structural Changes
A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.
Moderna Cancels mRNA Manufacturing Plant in Japan Amid Declining Vaccine Demand and Regulatory Uncertainty
Moderna has canceled plans to build an mRNA vaccine manufacturing plant at Shonan Health Innovation Park in Kanagawa Prefecture due to weak global vaccine demand and challenging business conditions.
Wacker Opens New Biotechnology Center in Munich to Accelerate Biopharmaceutical Research
Wacker Chemie has opened a new Biotechnology Center in Munich with space for 90 employees and state-of-the-art equipment to concentrate and intensify biotech research activities.
Sartorius Stedim Biotech Partners with Sensible Biotechnologies to Scale Cell-Based mRNA Manufacturing Platform
Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding to advance the industrialization of Sensible's first-in-class cell-based mRNA manufacturing platform.
Applied DNA Sciences Restructures Operations to Focus on Synthetic DNA Manufacturing for Gene Therapies
Applied DNA Sciences implemented a 27% workforce reduction and ceased operations at Applied DNA Clinical Labs to focus exclusively on its synthetic DNA manufacturing subsidiary LineaRx.
Laverock Therapeutics Raises £20M in Expanded Seed Funding, Reports Positive Data for Cancer Cell Therapy Programs
Laverock Therapeutics has expanded its seed funding round to more than £20 million, with the latest £6.5 million extension led by Calculus Capital and including participation from Eli Lilly and Company.
Liposomal Lipid Nanoparticles Show Enhanced Extrahepatic mRNA Delivery and Improved Stability
Researchers developed liposomal lipid nanoparticles (LNPs) with high bilayer lipid content that exhibit enhanced mRNA encapsulation and transfection potency compared to conventional Onpattro-like formulations.
CDC's Reconstituted Vaccine Advisory Panel Votes to Eliminate Thimerosal from All Flu Vaccines
The newly appointed Advisory Committee on Immunization Practices (ACIP) voted 5-1 to recommend thimerosal-free influenza vaccines for all age groups, despite the preservative being present in only 6% of U.S. flu vaccines.
Cambridge Healthcare Innovations Unveils Quattrii Inhaler Technology to Deliver Large-Dose Biologics and mRNA Therapies
Cambridge Healthcare Innovations has announced Quattrii, a dry powder inhaler engine capable of delivering large volumes of biologic and mRNA molecules in a single inhalation with at least 70% lung delivery efficiency.